Fox Run Management’s Momenta Pharmaceuticals, Inc. MNTA Stock Holding History

Fox Run Management’s Portfolio MNTA Stock Details MNTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-12,916	Closed	-$143K	–	778
2018 Q4	$143K	Buy	+12,916	New	+$180K	0.08%	446
2016 Q1	–	Sell	-10,500	Closed	-$156K	–	603
2015 Q4	$156K	Buy	+10,500	New	+$176K	0.12%	330

Other funds holding MNTA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Fox Run Management's MNTA Position: Q1 2019 in Review

Fox Run Management sold out of Momenta Pharmaceuticals, Inc. (MNTA) in Q1 2019, closing a stake of 12,916 shares — an estimated $143K sold.

Fox Run Management first reported a position in MNTA in Q4 2015 and held it in 2 quarters. The position peaked at $156K in Q4 2015. 147 funds tracked by Wall St. Rank hold MNTA as of Q1 2019.

Fox Run Management reported no remaining Momenta Pharmaceuticals, Inc. position as of Q1 2019 after selling out during the quarter.
Fox Run Management sold 12,916 Momenta Pharmaceuticals, Inc. shares in Q1 2019, an estimated $143K.
Fox Run Management first reported a position in Momenta Pharmaceuticals, Inc. in Q4 2015 and held it in 2 quarters.
Fox Run Management's Momenta Pharmaceuticals, Inc. position peaked at $156K in Q4 2015.
147 funds tracked by Wall St. Rank held Momenta Pharmaceuticals, Inc. as of Q1 2019.

Based on Fox Run Management's 13F filing for Q1 2019, filed 17 Oct 2019.